-
摘要: 人类免疫缺陷病毒(human immunodeficiency virus, HIV)感染靶细胞需要识别细胞表面CD4分子及其辅助受体, C-C趋化因子受体5(C-C chemokine receptor type 5, CCR5)和C-X-C趋化因子受体4(C-X-C-motif receptor 4, CXCR4)是HIV识别靶细胞的两种重要辅助受体。CCR5Δ32基因突变使得HIV无法识别CCR5受体, 从而阻止嗜CCR5的HIV病毒株入侵靶细胞。"柏林病人"和"伦敦病人"正是利用这一原理, 通过移植携带纯合子CCR5Δ32突变基因的异基因骨髓, 实现了停用抗病毒药物后病毒无反弹的目标, 故而被誉为HIV感染"治愈"案例。然而, 这一成功是否存在偶然性?事实上, 人群中携带CCR5Δ32纯合子基因突变概率极低、异基因骨髓配型十分困难、骨髓移植医疗费用昂贵、移植后HIV病毒株嗜性迁移等客观因素的存在, 使得通过携带纯合子CCR5Δ32基因突变异基因骨髓移植法实现HIV感染者停用抗病毒药物且保持病毒不反弹的目标困难重重。因此, "柏林病人"和"伦敦病人"的成功经验为治疗HIV感染提供了新的方向和希望, 但如认为HIV感染已被"治愈"为时尚早, 需进一步研究证实。Abstract: Infection with the human immunodeficiency virus (HIV) requires the presence of CD4 receptors and chemokine receptors. Two of the most principal chemokine receptors are C-C chemokine receptor 5 (CCR5) and/or the chemokine (C-X-C motif) receptor 4 (CXCR4). Homozygosity of a 32-bp deletion in the CCR5 allele provides resistance against the cellular entry of CCR5-tropic HIV strains. The successful long-term control of HIV by allogeneic haematopoietic stem cell transplantations (allo-HSCT) from a donor who was homozygous for CCR5 delta32, had been documented as a "Berlin patient" and a "London patient". They bothhad remained without viral recrudescence after transplantation and discontinuation of antiretroviral therapy. However, a wide application of allo-HSCT from donors with homozygous CCR5 delta32 mutation for HIV remission is still quite challenging so far under the condition of a low percentage of homozygous CCR5 delta32 mutation, high risk of allo-HSCT, HIV tropism shift after HSCT, and huge expense. Although the "Berlin patient" and the "London patient" take a new hope to control HIV infection, it is still too early to conclude that the "cure" of HIV infection has been achieved.
-
Key words:
- human immunodeficiency virus /
- Berlin patient /
- London patient /
- CCR5 delta 32 mutation
利益冲突 无 -
[1] Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation[J]. N Engl J Med, 2009, 360:692-698. doi: 10.1056/NEJMoa0802905 [2] Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation[J]. Nature, 2019, 568:244-248. doi: 10.1038/s41586-019-1027-4 [3] Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy[J]. AIDS, 2003, 17:S51-S60. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011 [4] Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion[J]. Nat Genet, 1997, 16:100-103. doi: 10.1038/ng0597-100 [5] Wang FS, Hong WG, Cao Y, et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF13'A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups[J]. J Acquir Immune Defic Syndr, 2003, 32:124-130. doi: 10.1097/00126334-200302010-00002 [6] Kordelas L, Verheyen J, Beelen DW, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation[J]. N Engl J Med, 2014, 371:880-882. https://pubmed.ncbi.nlm.nih.gov/25162903/ [7] Li Y, Han Y, Xie J, et al. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission[J]. AIDS, 2014, 28:521-530. doi: 10.1097/QAD.0000000000000125 [8] Gupta S, Neogi U, Srinivasa H, et al. HIV-1 coreceptor tropism in India:increasing proportion of X4-tropism in subtype C strains over two decades[J]. J Acquir Immune Defic Syndr, 2014, 65:397-404. doi: 10.1097/QAI.0000000000000046
点击查看大图
计量
- 文章访问数: 496
- HTML全文浏览量: 63
- PDF下载量: 29
- 被引次数: 0